• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medication isn't effective. Personalized treatment could be the solution.

Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We analyzed the best-fitting personalized ML models to each person, using Shapley values to determine their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet, only half of those with the condition receive cbt treatment for depression. To improve outcomes, clinicians need to be able to identify and treat patients with the highest likelihood of responding to specific treatments.

A customized depression treatment plan can aid. By using sensors on mobile phones as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to determine the biological and behavioral factors that predict response.

So far, the majority of research on predictors for depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographics like gender, age and education, as well as clinical characteristics like severity of symptom and comorbidities as well as biological markers.

Few studies have used longitudinal data to determine mood among individuals. They have not taken into account the fact that mood varies significantly between individuals. Therefore, it is crucial to develop methods that permit the recognition of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can detect various patterns of behavior and emotion that vary between individuals.

In addition to these modalities the team created a machine learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm integrates the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype has been correlated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely across individuals.

Predictors of Symptoms

Depression is one of the world's leading causes of disability1 yet it is often underdiagnosed and undertreated2. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many individuals from seeking help.

To help with personalized treatment, it is crucial to identify predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which aren't reliable and only reveal a few features associated with depression.

Machine learning is used to combine continuous digital behavioral phenotypes captured through smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing how depression is treated Inventory the CAT-DI) along with other indicators of symptom severity has the potential to improve the accuracy of diagnosis and the effectiveness of treatment for depression. These digital phenotypes allow continuous, high-resolution measurements. They also capture a wide range of distinctive behaviors and activity patterns that are difficult to capture using interviews.

The study enrolled University of California Los Angeles (UCLA) students who were suffering from moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA depression treatment london Grand Challenge. Participants were directed to online support or in-person clinical care depending on their depression severity. Participants who scored a high on the CAT DI of 35 or 65 were allocated online support with a peer coach, while those who scored 75 patients were referred to in-person clinical care for psychotherapy.

Participants were asked a series of questions at the beginning of the study concerning their demographics and psychosocial characteristics. The questions covered age, sex, and education as well as marital status, financial status as well as whether they divorced or not, the frequency of suicidal ideas, intent or attempts, as well as the frequency with which they consumed alcohol. Participants also rated their degree of depression symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI assessment was performed every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of holistic treatment for anxiety and depression Response

The development of a personalized depression treatment is currently a major research area and a lot of studies are aimed at identifying predictors that will allow clinicians to identify the most effective medications for each patient. Pharmacogenetics, for instance, uncovers genetic variations that affect how depression is treated the human body metabolizes drugs. This enables doctors to choose drugs that are likely to be most effective for each patient, minimizing the time and effort involved in trial-and-error procedures and avoiding side effects that might otherwise hinder the progress of the patient.

Another promising approach is to create prediction models that combine information from clinical studies and neural imaging data. These models can be used to identify the variables that are most predictive of a particular outcome, such as whether a medication will help with symptoms or mood. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness.

A new type of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of multiple variables to improve predictive accuracy. These models have shown to be effective in predicting treatment outcomes such as the response to antidepressants. These models are getting more popular in psychiatry and it is expected that they will become the standard for the future of clinical practice.

Research into depression's underlying mechanisms continues, in addition to predictive models based on ML. Recent findings suggest that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that individual depression treatment will be based on targeted treatments that target these circuits in order to restore normal function.

Internet-based interventions are a way to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a program on the internet was more effective treatments for depression than standard care in reducing symptoms and ensuring the best quality of life for people with MDD. Additionally, a randomized controlled study of a personalised treatment for depression demonstrated sustained improvement and reduced side effects in a significant number of participants.

Predictors of Side Effects

A major obstacle in individualized depression treatment is predicting which antidepressant medications will cause minimal or no side effects. Many patients are prescribed a variety of medications before finding a medication that is safe and effective. Pharmacogenetics is an exciting new avenue for a more effective and precise approach to choosing antidepressant medications.

A variety of predictors are available to determine the best antidepressant to prescribe, including genetic variations, phenotypes of patients (e.g., sex or ethnicity) and the presence of comorbidities. However, identifying the most reliable and accurate predictive factors for a specific treatment is likely to require controlled, randomized trials with considerably larger samples than those that are typically part of clinical trials. This is due to the fact that it can be more difficult to identify interactions or moderators in trials that comprise only one episode per participant instead of multiple episodes over a period of time.

In addition the prediction of a patient's response will likely require information on comorbidities, symptom profiles and the patient's personal perception of the effectiveness and tolerability. Presently, only a handful of easily identifiable sociodemographic and clinical variables appear to be correlated with the severity of MDD like gender, age race/ethnicity BMI and the presence of alexithymia and the severity of depression symptoms.

Many issues remain to be resolved in the application of pharmacogenetics for depression treatment. First, it is essential to be able to comprehend and understand the definition of the genetic factors that cause depression, as well as an accurate definition of a reliable indicator of the response to treatment. In addition, ethical concerns, such as privacy and the appropriate use of personal genetic information, should be considered with care. In the long-term, pharmacogenetics may provide an opportunity to reduce the stigma associated with mental health treatment and improve treatment outcomes for those struggling with depression. But, like any approach to psychiatry careful consideration and application is necessary. For now, the best method is to offer patients an array of effective depression medications and encourage them to speak freely with their doctors about their concerns and experiences.